ACEIs ace ARBs for type 2 diabetes

ACEIs come up trumps over ARBs for patients with type 2 diabetes, a meta-analysis suggests.

Challenging the tenet that there is little difference between the two drug classes, researchers found ACEIs reduced all-cause mortality by 13% and cardiovascular mortality by 17% compared with placebo or control drugs.

ARBs, by contrast, did not significantly reduce mortality compared to control medications, Chinese researchers wrote last week in JAMA Internal Medicine